| DB ID | MyCo_5902 |
| Title | Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG |
| Year | 2023 |
| PMID | 37620828 |
| Fungal Diseases involved | Pneumocystis jirovecii pneumonia |
| Associated Medical Condition | None |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | The study was approved by the ethics committee of the coordinating center (Liguria Region Ethics Committee, N. Registro CER Liguria 305/2021). Informed consent was waived due to the retrospective nature of the study. The other participating centers followed the local ethical requirements. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Italy |
| Cohort | The present retrospective, multicenter, multinational study, coordinated by San Martino Polyclinic Hospital in Genoa, Italy, was conducted in 8 different countries for a total of 18 participating centers (five in France, five in Italy, two in Germany, two in Spain, one in Bel- gium, one in Ireland, one in Sweden, and one in UK). Overall, 600 patients were included in the study. |
| Cohort No. | 600 |
| Age Group | None |
| P Value | p<0.0001 |
| Sensitivity | 1 |
| Specificity | 0.85 |
| Positive Predictive Value | 0.65 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pneumocystis jirovecii pneumonia (PJP) was most commonly described as an opportunistic, life-threatening disease in patients with human immunodeficiency virus (HIV) infection. However, due to the increased use of immunosuppressants, biologic agents, and corticosteroids for treating diseases such as inflammatory diseases, hematological malignancies, and solid neoplasms, novel populations at risk of PJP have emerged over the last decades, with reported mortality ranging from 33 to 69%. |
| Technique | PCR |
| Analysis Method | Respiratory Pneumocystis PCR |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Pneumocystis PCR, Serum (1–3)-ß-D Dextran Test Elisa |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
